Concerns regarding participation in HIV/AIDS clinical drug trials
| Primary topic | Concerns |
|---|---|
| Antiretroviral continuation | Lifelong duration |
| Until physician tells patient to stop | |
| Until a cure is available | |
| Unless side effects or resistance mandate cessation | |
| Duration clearly explained in consent process | |
| Monetary compensation | For trial participation |
| To purchase antiretroviral therapy | |
| To purchase food | |
| Awareness of potential abuse | |
| Patient/community education an additional compensation | |
| Follow up and treatment | General health care |
| Illness discovered during the trial | |
| Iatrogenic adverse events | |
| Moral obligation | To patient and community |
| For patients “helping” investigators | |
| For benefits investigators acquire | |
| For thorough informed consent | |
| Paternalistic need to protect patient | |
| Trial representation of all socioeconomic strata |